Treatment of Advanced Melanoma in 2020 and Beyond.
Treatment of Advanced Melanoma in 2020 and Beyond.
复制标题
DOI：
10.1016/j.jid.2020.03.943
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Fisher DE
中科院分区：
文献类型：
--
作者：
Jenkins RW;Fisher DE
在过去的十年里，黑色素瘤领域取得了前所未有的临床进展。对晚期或转移性黑色素瘤的治疗效果从反应最差的变成了反应最好的。也许最引人注目的是，改变疾病管理的进步是基于现代机制的治疗策略。主要抑制BRAF癌蛋白途径的靶向方法具有很高的疗效可预测性，但反应的最佳深度或持久性较差。免疫治疗主要基于阻断一个或两个免疫检查点，反应的可预测性较低，但持久缓解的比例较高。本文回顾了晚期黑色素瘤治疗的临床进展，并讨论了相同疗法对早期疾病的影响，其中药物在治疗可切除但高风险的临床情况方面显示出显着的希望。总的来说，黑色素瘤治疗的进展已经改变了患者的护理标准，为越来越多地用于治疗其他恶性肿瘤的新方法提供了信息，并为尚未从这些方法中获得最佳益处的许多患者提供了进一步提高疗效的新策略。
The melanoma field has seen an unprecedented set of clinical advances over the past decade. Therapeutic efficacy for advanced or metastatic melanoma went from being one of the most poorly responsive to one of the more responsive. Perhaps most strikingly, the advances that transformed management of the disease are based upon modern mechanism-based therapeutic strategies. The targeted approaches that primarily suppress the BRAF oncoprotein pathway have a high predictability of efficacy although less optimal depth or durability of response. Immunotherapy is primarily based on blockade of one or two immune checkpoints and has a lower predictability of response but higher fractions of durable remissions. This article reviews the clinical progress in management of advanced melanoma and also discusses the impact of the same therapies on earlier stage disease, where the agents have shown significant promise in treating resectable but high-risk clinical scenarios. Collectively, the progress in melanoma therapeutics has transformed the standard of care for patients, informed new approaches that are increasingly utilized for treatment of other malignancies, and suggest novel strategies to further boost efficacy for the many patients not yet receiving optimal benefit from these approaches.
登录
查看更多内容
DOI：
10.1056/nejmoa1613210
发表时间：
2017-06-08
期刊：
The New England journal of medicine
影响因子：
--
作者：
Faries MB;Thompson JF;Cochran AJ;Andtbacka RH;Mozzillo N;Zager JS;Jahkola T;Bowles TL;Testori A;Beitsch PD;Hoekstra HJ;Moncrieff M;Ingvar C;Wouters MWJM;Sabel MS;Levine EA;Agnese D;Henderson M;Dummer R;Rossi CR;Neves RI;Trocha SD;Wright F;Byrd DR;Matter M;Hsueh E;MacKenzie-Ross A;Johnson DB;Terheyden P;Berger AC;Huston TL;Wayne JD;Smithers BM;Neuman HB;Schneebaum S;Gershenwald JE;Ariyan CE;Desai DC;Jacobs L;McMasters KM;Gesierich A;Hersey P;Bines SD;Kane JM;Barth RJ;McKinnon G;Farma JM;Schultz E;Vidal-Sicart S;Hoefer RA;Lewis JM;Scheri R;Kelley MC;Nieweg OE;Noyes RD;Hoon DSB;Wang HJ;Elashoff DA;Elashoff RM
通讯作者：
Elashoff RM
影响因子：
64.8
作者：
Cabrita, Rita;Lauss, Martin;Jonsson, Goran
通讯作者：
Jonsson, Goran
影响因子：
51.1
作者：
Dummer, Reinhard;Brase, Jan C.;Long, Georgina, V
通讯作者：
Long, Georgina, V
影响因子：
10.9
作者：
Andtbacka, Robert H., I;Collichio, Frances;Kaufman, Howard L.
通讯作者：
Kaufman, Howard L.
影响因子：
45.3
作者：
Daud, Adil I.;Wolchok, Jedd D.;Hamid, Omid
通讯作者：
Hamid, Omid